Europe

Research into the therapeutic potential is taking place in countries all over Europe despite the varying legal statuses of psychedelics around the continent. Countries of note include Germany, Netherlands, Spain and Switzerland.

The European Medicines Agency (EMA) is responsible for regulatory oversight for its member states. In 2021, the EMA approved Spravato (esketamine) for people with major depressive disorder and suicidal ideation. Ultimately, it is the EMA who will determine the widespread accessibility of psychedelics and psychedelic-assisted therapies in the majority of European Union members.